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Introduction
Inflammation (Latin, inflammatio), is part of the body 
response to harmful stimuli. The stimuli can be disease 
causing organisms, damaged cells, irritants among others 
(1). Inflammation is meant to be protective and it involves 
blood vessels, immune cells and various inflammatory 
mediators (2). There are 5 classical signs of acute 
inflammation. These five signs are heat, pain, redness, 
edema and loss of function (3).
Resident cells such as dendritic, Kupffer, mastocytes, 
histocytes and macrophages, which are in diseased tissue, 
initiate the process of acute inflammation (4). Pattern 
recognition receptors (PPRs) are presented on the surface 
of these cells. These receptors recognize generic molecules 
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This study confirms the anti-inflammatory potential of the leaf and stem bark DCM-MeOH extracts of X. americana in 
experimental animals. Therefore, the DCM-MeOH leaf and stem bark extracts of X. americana might prove useful in managing 
inflammation and thus serve as an alternative treatment bioresource, which is more effective than the conventional synthetic 
drugs.
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Introduction: Ximenia americana is a highly branched shrub mainly found in tropics of Asia, 
Africa, New Zealand, Central and South America among others. In most parts of Africa, X. 
americana is used in folklore to treat various disorders such as oedema, pain, fever, helminthiasis, 
diarrhea and burns among others. There is no published data on anti-inflammatory activities 
of organic extracts of X. americana. It is against this background that this research was carried 
out. The study tested for the anti-inflammatory activities of dichloromethane-methanolic (DCM-
MeOH) leaf and stem bark extracts of X. americana in rats.
Methods: The plant materials were collected from Mbeere North sub-county, Embu county, Kenya. 
Methanol and dichloromethane in the ratio of 1:1 was used to extract the active compounds. Five 
to 6 weeks old Swiss Albino mice were employed for the anti-inflammatory studies. Animals were 
divided into 6 groups of 5 mice each: normal, negative, reference and three experimental groups (50, 
100 and 150 mg/kg body weight). Inflammation was induced experimentally using carrageenan. 
The experimental groups were treated with predetermined dose quantities of prepared extracts. 
Diclofenac was used as the reference drug. Data was analyzed using one-way analysis of variance 
(ANOVA). 
Results: The extracts from the leaves reduced hind paw circumference by between 0.91% 
and 16.90% while the stem bark extracts reduced hind paw circumference by between 5.84% 
and 29.00%. Diclofenac reduced right hind paw circumference by 1.32%-29.60%. Qualitative 
phytochemical screening showed presence of alkaloids, f lavonoids, steroids, saponins, cardiac 
glycosides, phenolics and terpenoids in the extract. 
Conclusion: The study established that the DCM-MeOH leaf and stem bark extracts of X. 
americana is effective in management of inflammation and therefore it can be explored as a 
possible bio-resource in the development of herbal medicines.
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broadly shared by disease causing organisms that are 
different from host molecules. They are collectively 
referred to as pathogen-associated molecular patterns (4).
During the onset of disease, the cells are activated; one 
of their PRRs recognizes pathogen associated molecular 
pattern (PAMP), causing the release of inflammatory 
mediators responsible for the cardinal signs of 
inflammatory process (4). Redness and increased heat on 
the damaged part is caused by vasodilatation that leads 
to increased blood flow. Edema is caused by increased 
permeability of blood vessels which results in leakage of 
plasma proteins and fluid into tissue. Pain is caused by 
increased sensitivity as result of released mediators such as 
bradykinin (4). Loss of function (disturbance of function) 
is the product of the neurological reflex in response to 
pain (4).
In laboratory animals, inflammation can be induced by use 
of carrageenan. Carrageenan is sulfated polysaccharide 
mainly used as food additive (5). Carrageenan is readily 
available in Kenyan market and is a widely studied agent 
for inducing inflammation in laboratory animals. The 
inflammatory response induced by carrageenan involves 
activation of Nuclear factor kappaB (NF-κB) by Toll like 
receptor (TLR) 4 and B-cell leukemia (BCL) 10 that leads 
to increased Interleukin (IL)-8 production (5).
Non-steroidal anti-inflammatory drugs (NSAIDs) such 
as diclofenac are used in the treatment of inflammation. 
These drugs confer anti-inflammatory activities through 
non-selective inhibition of cyclooxygenase enzymes 
(cyclooxygenase [COX] 1 and 2) which may result in 
serious side effects such as gastric bleeding (6). Such 
unwanted effects associated with the use of synthetic drugs 
can be avoided by alternatively using effective, tolerable 
and reliable naturally occurring agents (7).
Since time immemorial, plants have been used as 
source of medicine with many studies being carried out 
worldwide to confirm their efficacy (8). Traditionally, 
Ximenia americana is used in the treatment of a variety 
of disorders such as: pain, fever and inflammation (9,10), 
treatment of helminthiasis (11), diarrhea and wounds (12) 
and headaches, skin ulcers, kidney and heart problems 
(13). Mbeere community use X. americana to treat a 
stomach discomforts, fever, oedema, and pain. Despite the 
broad folklore use of X. americana, there is no scientific 
evaluation of its dichloromethane-methanolic (DCM-
MeOH) extracts on inflammation. The current study was 
designed against this background to specifically bioscreen 
DCM-MeOH stem bark and leaf extracts of X. americana 
for anti-inflammatory potential.
Materials and Methods
Collection and preparation of plant samples
Leaves and stem barks of X. americana were collected 
with the help of local traditional herbalists from Mbeere-
North in Embu county, Kenya. The plant materials were 
properly sorted, cleaned and packed in polythene bags 
and transported to biochemistry and biotechnology 
laboratories of Kenyatta University for further processing. 
The botanical authentication of the materials was done by a 
qualified taxonomist and the voucher specimen deposited 
in Kenyatta University Herbarium. The plant materials 
were chopped, completely air dried at room temperature 
followed by grinding into fine homogenous powder with 
an electric mill and then sieved through mesh sieve.
Extraction 
For each sample, 200 g of the powder was soaked in 
cold 1:1 mixture of methanol and DCM and stirred 
for 6 hours to extract the active compounds. This was 
followed by successive filtering of the extracts and the 
filtrate concentrated under reduced pressure and vacuum 
using rotary evaporator (Buchii R110). The concentrate 
was stored in airtight containers at -4oC before use in the 
bioassay studies (14).
Laboratory animals
Swiss Albino mice of either sex aged 5-6 weeks and weighing 
between 15-35 g were employed in the study (15). The 
animals were acquired and bred at the animal breeding 
and experimentation laboratory in Kenyatta University, 
Department of Biochemistry and Biotechnology. The 
animals were kept in standard cages, under the conditions 
of a standard laboratory of ambient temperature of 
25oC and 12-hour light followed by 12-hour dark cycle 
throughout the experiments. The feeding was on standard 
pellets for rodents and water was supplied in ad libitum 
(16). Throughout the study, all ethical guidelines and 
procedures on animal handling were followed (17).
Determination of anti-inflammatory activities
The experimental animals (30 Swiss Albino mice) were 
divided into 6 groups of 5 mice each and treated as shown 
in Table 1. 
The carrageenan, (0.1 mL and 1% w/v in normal saline), 
was used to induce inflammation by injecting into 
the sub-plantar of the right hind paw tissue (18). One 
hour after induction of inflammation, herbal extracts 
and DMSO were intraperitoneally administered. The 
inflammation was measured immediately prior to the 
injection of carrageenan and the comparison of the paw 
circumference was done after injection of carrageenan. 
The measurement of linear paw circumference was done 
at an interval of 1 hour for 4 hours and comparison was 
done according to the following formula (19):
1 0
1
0
100t tE
t
−
= ×
Where t0 = initial volume of paw, t1= final volume of the 
paw. 
Qualitative Phytochemical Screening 
Qualitative phytochemical screening was done on the 
extracts to find out whether selected phytochemicals were 
present (20,21). The secondary metabolites tested for are: 
alkaloids, tannins, steroids, saponins, cardiac glycosides, 
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phenolics and terpenoids.
Management and statistical analysis of the data
The data on the right hind paw circumference changes 
was recorded and tabulated in a spread sheet. The data 
was then imported to Minitab statistical software version 
17 for descriptive statistical analysis. The results were 
expressed as mean ± standard error (SE) of mean for 
analysis. One-way analysis of variance (ANOVA) was 
performed to compare the group means followed by 
Tukey’s post hoc test for pair-wise mean separations and 
comparisons to obtain the specific significant differences 
among the different groups. Unpaired student t test was 
used to compare mean anti-inflammatory activities 
between leaf and stem bark extracts of X. americana.
The statistical significance was considered at P ≤ 0.05. 
The data on the percentage change in paw circumference 
was presented using graphs.
Results
Anti-inflammatory activity of DCM-MeOH leaf extract of 
Ximenia americana in mice
The DCM-MeOH leaf extracts of X. americana at the 3 
dose levels (50, 100 and 150 mg/kg body weight) reduced 
right hind paw circumference of carrageenan-induced in-
flammation in mice (Table 2; Figure 1). 
In the first hour, the 3 dose levels (50, 100 and 150 mg/kg 
body weight) reduced paw circumference by 0.91%, 2.28% 
and 2.30% respectively (Figure 1). The anti-inflammatory 
activities of the leaf extract of X. americana at the 3 
dose levels showed no significant difference from the 
positive group (P ˃  0.05; Table 2). The anti-inflammatory 
activities at dose levels 100 and 150 mg/kg body weight 
was significantly different from the normal and negative 
groups (P < 0.05; Table 2).
In the second hour, the 3 dose levels of the extract (50, 
100 and 150 mg/kg body weight) reduced the paw 
circumference by 8.47%, 11.62% and 7.85% respectively. 
There was significant difference between the 3 dose levels 
of extract from the normal and negative control group 
at this hour (P < 0.05; Table 2). The anti-inflammatory 
effects of the extract at dose level 50 and 150 mg/kg body 
weight showed no significant difference from the positive 
group at this hour (P ˃  0.05; Table 2).
In the third hour, the 3 dose levels of leaf extract of X. 
americana (50, 100 and 150 mg/kg body weight) reduced 
the right hind paw circumference of mice by 14.54%, 
15.04% and 16.90% respectively (Figure 1). The difference 
in anti-inflammatory activities of extract was significant 
from both normal group and negative group (P < 0.05; 
Table 2) but there was no significant difference when 
compared to that of diclofenac (P ˃  0.05; Table 2).
In the fourth hour, the 3 dose levels of the leaf extract 
of X. americana (50, 100 and 150 mg/kg body weight) 
reduced the paw circumference of mice by 2.61%, 15.94% 
and 9.01% respectively (Figure 1). The anti-inflammatory 
activity of the extract at this hour for all the dose levels was 
significantly different from the normal group and negative 
group (P < 0.05; Table 2). The anti-inflammatory activity 
of the leaf extract at the dose level of 100 mg/kg body 
weight showed no significant difference from the positive 
control group at this hour (P ˃  0.05; Table 2).
Anti-inflammatory activity of DCM-MeOH stem bark 
extract of Ximenia americana in mice
The DCM-MeOH stem bark extract of X. americana 
showed similar anti-inflammatory activities against 
carrageenan-induced inflammation in mice (Table 3 and 
Table 1. Treatment protocol for evaluation of anti-inflammatory activities of DCM-MeOH leaf and stem bark extracts Ximenia americana in mice
Group Status Treatment
I Normal control                  DMSOa
II Negative control                Carrageenan 100 μg  + DMSO (10%)
III Positive control                 Carrageenan 100 μg  + 15 mg/kg diclofenac
IV Experimental  group A       Carrageenan 100 μg  + 50 mg/kg extract
V Experimental  group B      Carrageenan 100 μg  + 100 mg/kg extract
VI Experimental  group C      Carrageenan 100 μg  + 150 mg/kg extract
a DMSO was used as a vehicle.
Table 2. Effects of DCM-MeOH leaf extract of Ximenia americana on carrageenan-induced inflammation in mice
Group Treatment
Percent change in paw circumference after drug administration
0 h 1 h 2 h 3 h 4 h
Normal control DMSO 100 ± 0.00 99.997 ± 0.16a 100.01 ± 0.15a 99.921 ± 0.18a 100.10 ± 0.10a
Negative control Carrageenan + DMSO 100 ± 0.00 100.46 ± 0.18a 103.46 ± 1.73a 103.74 ± 1.73a 103.79 ± 1.65a
Positive control Carrageenan + DMSO + diclofenac 100 ± 0.00 98.684 ± 0.40ab 94.986 ± 0.67b 82.34 ± 2.37b 81.40 ± 1.46d
DCM: Methanolic
Leaf extract
Carrageenan + 50 mg/kg 100 ± 0.00 99.090 ± 0.22ab 91.526± 0.98bc 85.46 ± 1.71b 97.39 ± 2.43ab
Carrageenan + 100 mg/kg 100 ± 0.00 97.715 ± 0.58b 88.38 ± 1.80c 84.96 ± 1.85b 84.06 ± 1.91cd
Carrageenan + 150 mg/kg 100 ± 0.00 97.700 ± 0.87b 92.149 ± 0.36bc 83.10 ± 1.75b 90.99 ± 2.24bc
Values are expressed as Mean ± SEM for 5 animals per group. Statistical comparison were made within a column and values with the same superscript 
are not significantly different by one-way ANOVA followed by Tukey’s post hoc test (P  ˃ 0.05). Carrageenan =1%; DMSO = 10%; Diclofenac = 15 mg/kg.
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Figure 2). This was indicated by the reduction in the paw 
circumference.
In the first hour, the 3 dose levels (50, 100 and 150 mg/kg 
body weight) reduced the right hind paw circumference 
by 5.848%, 9.174% and 10.27% respectively (Figure 2 
and Table 3). In comparison to the diclofenac, the anti-
inflammatory activities at the 3 dose levels of the extract 
did not show significant difference (P ˃  0.05; Table 3). The 
3 dose levels of the stem bark extract (50, 100 and 150 mg/
kg body weight) showed significant difference from the 
negative control group (P < 0.05; Table 3).
In the second hour, the 3 dose levels of the extract reduced 
the right hind paw circumference by 13.72% and 19.17% 
and 20.33% respectively as shown (Figure 2 and Table 3). 
The anti-inflammatory activities of the stem bark extract 
of X. americana at the 3 dose levels did not show significant 
difference from diclofenac (P ˃  0.05; Table 3). The 3 dose 
levels showed significant difference from the normal and 
negative control groups (P < 0.05; Table 3). 
The 3 dose levels of the stem bark extract of X. americana 
(50, 100 and 150 mg/kg body weight) reduced the paw 
circumference of mice by 23.18%, 23.91% and 25.97% 
respectively in the third hour (Figure 2). There was no 
significant difference of the anti-inflammatory activities 
at all the 3 dose levels from the positive control (P ˃  0.05; 
Table 3). This was as opposed to the anti-inflammatory 
activity of the 3 dose levels of the extract which was 
significantly different from the normal group and negative 
control group (P < 0.05; Table 3)
In the fourth hour, the 3 dose levels of the extract (50, 
100 and 150 mg/kg body weight) and diclofenac reduced 
inflamed hind paw circumference by 8.62%, 27.73%, 
29.00% and 29.60% respectively (Figure 2 and Table 3). 
The dose levels of 100 and 150 mg/kg body weight showed 
no significant difference from the positive control group 
(P ˃  0.05; Table 3). The dose level of 50 mg/kg body weight 
showed significant difference from the positive control 
group (P < 0.05; Table 3). The highest anti-inflammatory 
activity was associated with the dose level of 150 mg/kg 
body weight whereby circumference of inflamed paw 
was decreased by 29%. However, the anti-inflammatory 
activity at the dose level of 50 mg/kg body weight of 
the extract was significantly different from 100 and 150 
mg/kg body weight (P < 0.05; Table 3) but there was no 
significant difference from the normal control group 
(P ˃  0.05; Table 3). 
Comparison between the anti-inflammatory activities of 
leaf and stem bark extract of Ximenia americana
In comparison, at the dose level of 50 mg/kg, there was 
significant difference in the anti-inflammatory activities of 
DCM-MeOH leaf and stem bark extracts of X. americana 
in the first and third hour of the test period (P = 0.05 and 
0.006 respectively). However, there was no significant 
Figure 1. Anti-inflammatory effects of DCM-MeOH leaf extract 
of Ximenia americana on carrageenan-induced inflammation in 
Swiss albino mice.
Figure 2. Anti-inflammatory effects of DCM-MeOH stem 
bark extract of Ximenia americana on carrageenan-induced 
inflammation in mice.
Table 3. Effects of DCM-MeOH stem bark extract of Ximenia americana on carrageenan-induced inflammation in mice
Group Treatment
Percent change in paw circumference after drug administration
0 h 1 h 2h 3h 4h
Normal control DMSO 100 ± 0.00 100.00 ± 0.21b 99.967 ± 0.06b 100.06 ± 0.07b 99.939 ± 0.06b
Negative control Carrageenan + DMSO 100 ± 0.00 130.97 ± 3.85a 133.45 ± 3.32a 133.97 ± 3.44a 134.34 ± 3.40a
Positive control Carrageenan + DMSO + diclofenac 100 ± 0.00 90.020 ± 0.43c 79.915 ± 0.66c 73.06 ± 1.97c 70.40 ± 1.70c
DCM: Methanolic
stem bark extracts
Carrageenan + 50 mg/kg 100 ± 0.00 94.160 ± 1.82bc 86.28± 2.29c 76.82 ± 1.40c 91.38 ± 2.91b
Carrageenan + 100 mg/kg 100 ± 0.00 90.826 ± 0.90c 80.83± 1.83c 76.09 ± 1.19c 72.27 ± 1.80c
Carrageenan + 150 mg/kg 100 ± 0.00 89.731 ± 0.68c 79.67 ±1.60c 74.03 ± 1.55c 71.004 ± 0.94c
Values are expressed as Mean ± SEM for 5 animals per group. Statistical comparison were made within a column and values with the same superscript 
are not significantly different by one-way ANOVA followed by Tukey’s post hoc test (P  ˃ 0.05). Carrageenan =1%; DMSO = 10%; Diclofenac = 15 mg/kg.
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difference in the second and fourth hour at this dose level 
(P = 0.08 and 0.157 respectively) (Figure 3).
At the dose level of 100 mg/kg, there was significant 
difference in the anti-inflammatory activities of the DCM-
MeOH leaf and stem bark extracts of X. americana for the 
4 hours of the test period (P = 0.001, 0.022, 0.007 and 0.003 
respectively) (Figure 3).
At the dose level of 150 mg/kg, there was significant 
difference in the anti-inflammatory activities of the DCM-
MeOH leaf and stem bark extracts of X. americana for the 
4 hours of the test period (P = 0.000, 0.002, 0.006 and 0.000 
respectively) (Figure 3).
Qualitative phytochemical screening
The qualitative phytochemical screening of DCM-MeOH 
leaf and stem bark extracts of X. americana showed the 
presence of alkaloids, cardiac glycosides, flavonoids, 
phenolics, saponins and terpenoids. However, alkaloids 
and terpenoids were absent in the leaf extract of the X. 
americana while the steroids were absent in both leaf and 
stem bark extracts (Table 4).
Discussion
The present study was designed to evaluate the anti-
inflammatory activities of DCM-MeOH leaf and stem 
Figure 3. Comparison of percentage reduction in paw 
circumference of DCM-MeOH leaf and stem bark extract of 
Ximenia americana on carrageenan-induced inflammation in 
mice. 
Table 4. Qualitative phytochemical composition of DCM-MeOH leaf 
and stem bark extracts of Ximenia americana
Phytochemicals Ximenia americana leaf extract
Ximenia americana stem 
bark extract
Alkaloids - +
Flavonoids (+) (+)
Steroids - -  
Saponins  (+) (+)
Cardiac glycosides + +
Phenolics (+) (+)
Terpenoids - +
Present phytochemical are denoted by (+) sign, absent phytochemical 
are denoted by (-) sign while + (trace) denotes slightly present 
phytochemical.
bark extracts of X. americana in rat models.
The DCM-MeOH leaf and stem bark extracts of X. 
americana showed a significant anti-inflammatory activity 
on carrageenan-induced paw edema in mice (Tables 2 and 
3). The standard screening models for inflammation in 
experimental animals comprise of carrageenan-induced 
hind paw edema, cotton pellet induced granuloma and 
Freund’s adjuvant (22). 
Carrageenan is a natural carbohydrate obtained from 
edible seaweeds and is generic name for a family of 
gel-forming polysaccharides seaweeds (23). There is a 
very wide use of carrageenan as an agent for inducing 
inflammation (24). Carrageenan solution 1% in normal 
saline for intraplantar injection at the dosage of 50-150 µL 
is readily used (25). Carrageenan induces inflammation 
in two phases; early phase (90-180 minutes) characterized 
by the release of histamines and serotonins while the 
late phase (270-360 minutes) characterized by release of 
prostaglandins, lysosomes and proteases (26,27). Thus, 
carrageenan was used as the phlogistic agent for the 
present study.
The DCM-MeOH leaf and stem bark extracts of X. 
americana produced significant anti-inflammatory 
activities on carrageenan-induced paw edema in Swiss 
albino mice (Tables 2 and 3). These findings relate with the 
activity of various herbal plants tested in animal models. 
The aqueous ethanol root bark extract of the X. americana 
extract (10 and 100 mg/kg body weight) showed a 
significant inhibition of carrageenan-induced mice paw 
inflammation in which the anti-inflammatory effects were 
proportional to the dose concentration (28). Similar work 
on aqueous extract of Bauhinia purpurea leaves in animal 
models demonstrated significant anti-inflammatory 
activity on carrageenan-induced inflammation (29). 
Similarly, there was effective anti-inflammatory effect of 
the ethanolic and aqueous extracts of Kalanchoe pinnata 
on carrageenan induced edema in rats (30).
Nonsteroidal drugs such as diclofenac, ibuprofen, 
indomethacin among others are routinely prescribed in 
the management of inflammation (31). These drugs work 
by inhibiting prostaglandin biosynthesis by blocking 
the enzyme cyclooxygenases (COX) (32). Therefore, the 
anti-inflammatory activities of the leaf and stem bark 
extracts of X. americana to manage inflammation may be 
attributed to the inhibition of prostaglandin synthesis.
The anti-inflammatory effect of the DCM-MeOH extracts 
of X. americana at the dose levels of (50, 100 and 150 mg/
kg body weight), over a period of 3 hours in carrageenan-
induced inflammation was comparable to that exhibited 
by the positive control group. Previous studies with 
some other plants such as Maytenus obscura, Caesalpinia 
volkensii (33) and Solanum trilobatum (34) also showed 
a similar effect in this model. The findings demonstrate 
that the extracts act in a dose dependent manner in the 
late phase which might be involving arachidonic acid 
metabolites as they are associated with edema reliant on 
mobilization of neutrophils. This dose dependent trend 
might be attributed to the passive diffusion of bioactive 
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molecules through plasma membrane from peritoneal 
cavity.
In determination of anti-inflammatory activities of the 
extract in mice, 3 dose levels (50,100 and 150 mg/kg body 
weight) were used. Similar studies carried out in evaluating 
anti-inflammatory activities of medicinal plants in animal 
models employed similar dose ranges (33,35,36).
The anti-inflammatory effect of both extracts was 
comparable to the group treated with diclofenac. The leaf 
extract of X. americana reduced the paw edema by between 
0.91%-16.90% while the stem bark extract reduced it by 
between 5.84% and 28.99%. Diclofenac reduced the paw 
edema by between 1.32% and 29.6%. Thus, the extracts 
possess anti-inflammatory potential comparable to the 
reference drug (diclofenac) and can be considered as 
suitable anti-inflammatory agent.
The anti-inflammatory activity of the DCM-MeOH leaf 
and stem bark extracts of X. americana may be due to 
the presence of phytochemical constituents. Qualitative 
phytochemical screening of the leaf extract confirmed 
presence of saponins, flavonoids, cardiac glycosides and 
phenolics while the stem bark extract shoed presence 
of alkaloids, flavonoids, saponins, cardiac glycosides, 
phenolics and terpenoids (Table 4). The presence of 
these phytochemicals has been associated with the anti-
inflammatory activities in the animal models (37).
Conclusion
In conclusion, the present study confirms the anti-
inflammatory potential of the leaf and stem bark DCM-
MeOH extracts of X. americana in experimental animals. 
The significant reduction in right hind paw circumference 
which was comparable to the reference drug shows 
that these extracts are endowed with significant anti-
inflammatory activities.
Therefore, the DCM-MeOH leaf and stem bark extracts 
of X. americana might prove useful in managing 
inflammation and thus serve as an alternative treatment 
bioresource, which is more effective than the conventional 
synthetic drugs.
The present study showed that DCM-MeOH leaf and 
stem bark extracts of X. americana contain a class 
of phytochemicals attributable to anti-inflammatory 
properties. Therefore, the study scientifically confirms 
and supports the use of X. americana in traditional 
management of inflammation.
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